부산대학교 도서관

Radiotherapy was administered alongside systemic therapy with nivolumab, defined as radiotherapy within 8 weeks of prior systemic therapy, in 16 of 76 patients (21%). Only patients who commenced nivolumab prior to radiotherapy and subsequently continued with nivolumab therapy following radiotherapy were included in the analysis, and patients who had radiation after nivolumab discontinuation were not classified as having multi-modality radio-immunotherapy for the purposes of this study. In this study, we have demonstrated that in a population of patients with platinum-resistant recurrent and metastatic HNSCC treated with nivolumab, radiotherapy was administered in addition in 21% of patients, although radiotherapy and continued nivolumab were only administered in 12%. Keywords: head and neck cancer; immunotherapy; nivolumab; radiotherapy EN head and neck cancer immunotherapy nivolumab radiotherapy 606 610 5 08/05/22 20220901 NES 220901 Key Points This study reports clinical outcome data on 76 patients with platinum-resistant recurrent or metastatic head and neck squamous carcinoma treated with nivolumab, making it the largest published single-centre case series of its kind. [Extracted from the article]